AgomAb Therapeutics (AGMB) Stock Price, News & Analysis

Company Overview

Agomab Therapeutics N.V. is a clinical-stage biotechnology company developing antibody-based medicines designed to activate biological pathways involved in tissue repair and regeneration. The company focuses on serious diseases in which restoring or rebuilding damaged tissue could provide therapeutic benefit.

Agomab’s lead program, AGMB-129, is an investigational, gut-restricted agonist of fibroblast growth factor receptor 1c (FGFR1c) being developed for inflammatory bowel disease, including Crohn’s disease. The company’s approach is intended to stimulate intestinal mucosal healing while limiting unwanted effects outside the gastrointestinal tract.

In addition to AGMB-129, Agomab is advancing a broader pipeline of regenerative medicine programs addressing fibrosis, oncology and other conditions associated with tissue damage or impaired repair. The company was founded in 2017 and operates as a biotechnology company with activities in Europe and the United States.

Key Stats

• Today's Range: $8.92 to $9.49
• 50-Day Range: $8.56 to $15.78
• 52-Week Range: $7.97 to $17.82
• Volume: 102,087 shs
• Average Volume: 179,520 shs
• Market Capitalization: $329.03 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $37.50
• Consensus Rating: Moderate Buy

AgomAb Therapeutics Stock Analysis - MarketRank™

AgomAb Therapeutics scored higher than 79% of companies evaluated by MarketBeat, and ranked 110th out of 883 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

AgomAb Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on no strong buy ratings, 7 buy ratings, 1 hold rating, and no sell ratings.

Upside Potential

AgomAb Therapeutics has a consensus price target of $37.50, representing about 313.0% upside from its current price of $9.08.

Amount of Analyst Coverage

AgomAb Therapeutics has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for AgomAb Therapeutics are expected to decrease in the coming year, from ($1.76) to ($2.06) per share.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

2.76% of the float of AgomAb Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

AgomAb Therapeutics has a short interest ratio ("days to cover") of 7.12.

Change versus previous month

Short interest in AgomAb Therapeutics has recently increased by 15.38%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

AgomAb Therapeutics does not currently pay a dividend.

Dividend Growth

AgomAb Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 4.7 / 5
• News Sentiment: 1.53

News Sentiment

AgomAb Therapeutics has a news sentiment score of 1.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.64 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 14 news articles for AgomAb Therapeutics this week, compared to 3 articles on an average week.

Search Interest

1 people have searched for AGMB on MarketBeat in the last 30 days.

MarketBeat Follows

4 people have added AgomAb Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.6 / 5
• Insider Trading: Acquiring Shares

Cluster Insider Buying

3 insiders have purchased shares of AgomAb Therapeutics in the last three months. Multiple insiders buying is a strong bullish signal.

Net Insider Buying

Over the last three months, insiders have purchased a net $268,280.00 in company stock, which represents 0.0815% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, AgomAb Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $268,280.00 in company stock and sold $0.00 in company stock.

Percentage Held by Institutions

AgomAb Therapeutics has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 10/10/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:AGMB
• CIK: 2020932
• Web: www.agomab.com
• Phone: (323) 302-3530
• Fax: N/A
• Employees: 62
• Year Founded: 2017

Price Target and Rating

• Average Price Target for AgomAb Therapeutics: $37.50
• High Price Target: $60.00
• Low Price Target: $28.00
• Potential Upside/Downside: +313.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.88
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 12.88
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 36,237,000
• Free Float: N/A
• Market Cap: $329.03 million
• Optionable: N/A
• Beta: N/A